MA38884A1 - Composé de triazolopyridine, compositions et procédés d'utilisation associés - Google Patents

Composé de triazolopyridine, compositions et procédés d'utilisation associés

Info

Publication number
MA38884A1
MA38884A1 MA38884A MA38884A MA38884A1 MA 38884 A1 MA38884 A1 MA 38884A1 MA 38884 A MA38884 A MA 38884A MA 38884 A MA38884 A MA 38884A MA 38884 A1 MA38884 A1 MA 38884A1
Authority
MA
Morocco
Prior art keywords
methods
compositions
triazolopyridine compound
formula
triazolopyridine
Prior art date
Application number
MA38884A
Other languages
English (en)
Inventor
Snahel Patel
Wei Li
Matthew W Cartwright
Christine Edwards
Simon C Goodacre
Nicholas C Ray
Mohammed Sajad
Po-Wai Yuen
Mark E Zak
Yun-Xing Cheng
Original Assignee
Hoffmann La Roche
Genentech Inc
Wei Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Genentech Inc, Wei Li filed Critical Hoffmann La Roche
Publication of MA38884A1 publication Critical patent/MA38884A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des composés de formule 0, de formule i et de formule ii et des procédés d'utilisation en tant qu'inhibiteurs de janus kinase.
MA38884A 2013-09-05 2014-08-27 Composé de triazolopyridine, compositions et procédés d'utilisation associés MA38884A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361874038P 2013-09-05 2013-09-05
PCT/CN2014/085276 WO2015032286A1 (fr) 2013-09-05 2014-08-27 Composé de triazolopyridine, compositions et procédés d'utilisation associés

Publications (1)

Publication Number Publication Date
MA38884A1 true MA38884A1 (fr) 2017-06-30

Family

ID=52627792

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38884A MA38884A1 (fr) 2013-09-05 2014-08-27 Composé de triazolopyridine, compositions et procédés d'utilisation associés

Country Status (17)

Country Link
US (4) US20160185780A1 (fr)
EP (1) EP3041841B1 (fr)
JP (1) JP6472803B2 (fr)
KR (1) KR20160050080A (fr)
CN (1) CN105745209B (fr)
AU (1) AU2014317600A1 (fr)
CA (1) CA2922770A1 (fr)
CL (1) CL2016000496A1 (fr)
CR (1) CR20160070A (fr)
EA (1) EA201690523A1 (fr)
IL (1) IL244066A0 (fr)
MA (1) MA38884A1 (fr)
MX (1) MX2016002764A (fr)
PE (1) PE20161323A1 (fr)
PH (1) PH12016500347A1 (fr)
SG (1) SG11201601707PA (fr)
WO (1) WO2015032286A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507236A (ja) * 2015-03-04 2018-03-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾロピリジン化合物及びその使用法
JP6929286B2 (ja) * 2015-12-18 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 治療用化合物、組成物及びその使用方法
JP6832342B2 (ja) * 2016-03-31 2021-02-24 武田薬品工業株式会社 複素環化合物
BR112019004486A2 (pt) 2016-09-06 2019-05-28 Hoffmann La Roche compostos de 8-(azetidin-1-il)-[1,2,4] triazolo [1,5a] piridinil, composições e métodos de uso dos mesmos
CN109400610A (zh) * 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
WO2022187804A1 (fr) * 2021-03-02 2022-09-09 Icahn School Of Medicine At Mount Sinai Inhibiteurs à base de benzoxazolone d'inflammasomes
TW202334136A (zh) * 2021-11-03 2023-09-01 美商傳達治療有限公司 PI3Kα抑制劑及其製造與使用方法
US11746108B1 (en) * 2022-06-13 2023-09-05 Apm Therapeutics 1, Inc. Triazolopyridine polymorph A

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
EP1241176A1 (fr) 2001-03-16 2002-09-18 Pfizer Products Inc. Dérivés de purine pour le traitement de l'ischémie
US6693116B2 (en) 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
WO2008065198A1 (fr) 2006-12-01 2008-06-05 Galapagos N.V. Composés de triazolopyridine pour le traitement de maladies dégénératives et inflammatoires
WO2009017954A1 (fr) * 2007-08-01 2009-02-05 Phenomix Corporation Inhibiteurs de kinase jak2
MX2010014005A (es) 2008-06-20 2011-02-15 Genentech Inc Compuestos de triazolopiridina inhibidores de jak y los metodos.
PE20110063A1 (es) * 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010010186A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010184A1 (fr) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak
WO2010010188A1 (fr) 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
WO2010141796A2 (fr) * 2009-06-05 2010-12-09 Cephalon, Inc. Préparation et utilisation de dérivés de 1,2,4-triazolo[1,5a]pyridine
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
US8486967B2 (en) * 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체

Also Published As

Publication number Publication date
US20190233441A1 (en) 2019-08-01
CN105745209B (zh) 2018-10-23
JP2016529299A (ja) 2016-09-23
US9873709B2 (en) 2018-01-23
PE20161323A1 (es) 2016-11-25
CN105745209A (zh) 2016-07-06
CL2016000496A1 (es) 2016-10-07
IL244066A0 (en) 2016-04-21
EA201690523A1 (ru) 2016-07-29
AU2014317600A1 (en) 2016-03-03
EP3041841A1 (fr) 2016-07-13
JP6472803B2 (ja) 2019-02-20
CR20160070A (es) 2016-04-01
CA2922770A1 (fr) 2015-03-12
MX2016002764A (es) 2016-05-26
US20180298033A1 (en) 2018-10-18
US20160185780A1 (en) 2016-06-30
EP3041841B1 (fr) 2019-06-05
KR20160050080A (ko) 2016-05-10
EP3041841A4 (fr) 2017-04-19
WO2015032286A1 (fr) 2015-03-12
SG11201601707PA (en) 2016-04-28
US20170226132A1 (en) 2017-08-10
PH12016500347A1 (en) 2016-05-16

Similar Documents

Publication Publication Date Title
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
MA44820A1 (fr) Amides hétérocycliques a utiliser en tant qu'inhibiteurs de kinase
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
MA42109B1 (fr) Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
EA201691916A1 (ru) Биарильные ингибиторы киназы
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
RS54492B1 (en) KINASE INHIBITOR REGULATING THE SIGNAL PATH OF APOPTOSIS
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
MX2016009352A (es) Inhibidores de quinasa a base de quinolina.
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
WO2016164295A3 (fr) Pyridines fusionnées en tant qu'inhibiteurs de kinase
EA201891866A1 (ru) N,N-ДИМЕТИЛ-3-[[5-(3-МЕТИЛ-2-ОКСО-1-ТЕТРАГИДРОПИРАН-4-ИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-8-ИЛ)-2-ПИРИДИЛ]ОКСИ]ПРОПАН-1-АМИНОКСИД В КАЧЕСТВЕ МОДУЛЯТОРА АТМ-КИНАЗЫ (МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ) ДЛЯ ЛЕЧЕНИЯ РАКА
RS54689B1 (en) CONNECTED BICYCLIC 2,4- DIAMINOPYRIMIDINE DERIVATIVE AS DUAL ALK AND FAK INHIBITOR